CIK: 0001687078 · Show all filings
Period: Q4 2024 (← Previous) (Next →)
Filing Date: Feb 14, 2025
Total Value ($000): $704,362 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | 7,648,268 | $93,156 | 13.2% | $40.60 | -64.6% | Common | 230031106 |
| CRNX | Crinetics Pharmaceuticals Inc. | 617,035 | $31,549 | 4.5% | $29.28 | +91.1% | Common | 22663K107 |
| EWTX | Edgewise Therapeutics Inc | 1,079,316 | $28,818 | 4.1% | $19.37 | +64.4% | Common | 28036F105 |
| INSM | Insmed Incorporated | 389,611 | $26,899 | 3.8% | $21.93 | +228.4% | Common | 457669307 |
| NTRA | Natera Inc | 160,626 | $25,427 | 3.6% | $76.08 | +91.5% | Common | 632307104 |
| MIRM | Mirum Pharmaceuticals Inc | 589,579 | $24,379 | 3.5% | $28.76 | +44.9% | Common | 604749101 |
| IRON | Disc Medicine Inc | 346,401 | $21,962 | 3.1% | $44.49 | +30.0% | Common | 254604101 |
| LNTH | Lantheus Holdings Inc | 236,213 | $21,132 | 3.0% | $82.12 | +18.6% | Common | 516544103 |
| ZLAB | Zai Lab Ltd | 800,000 | $20,952 | 3.0% | $26.19 | — | Common | 98887Q104 |
| RNAM | Avidity Biosciences Inc | 702,981 | $20,443 | 2.9% | $40.75 | +2.6% | Common | 05370A108 |
| IOVA | Iovance Biotherapeutics Inc | 2,673,905 | $19,787 | 2.8% | $9.95 | -6.8% | Common | 462260100 |
| PTCT | PTC Therapeutics Inc | 434,767 | $19,625 | 2.8% | $40.88 | +4.7% | Common | 69366J200 |
| WVE | Wave Life Sciences PTE LTD | 1,489,237 | $18,422 | 2.6% | $10.26 | +30.1% | Common | Y95308105 |
| SRRK | Scholar Rock Holding Corp. | 416,144 | $17,986 | 2.6% | $32.56 | 0.0% | Common | 80706P103 |
| MLTX | Moonlake Immunotherapeutics | 315,230 | $17,070 | 2.4% | $29.33 | +74.1% | Class A Ord | 61559X104 |
| OLMA | Olema Pharmaceuticals, Inc. | 2,912,550 | $16,980 | 2.4% | $9.76 | +2.3% | Common | 68062P106 |
| RARE | Ultragenyx Pharmaceutical Inc | 391,018 | $16,450 | 2.3% | $46.22 | +7.3% | Common | 90400D108 |
| CNTX | Context Therapeutics Inc | 14,705,882 | $15,441 | 2.2% | $1.73 | 0.0% | Common | 21077P108 |
| GH | Guardant Health Inc | 452,739 | $13,831 | 2.0% | $23.27 | +20.9% | Common | 40131M109 |
| RVMD | Revolution Medicines, Inc. | 313,817 | $13,726 | 1.9% | $29.19 | +72.9% | Common | 76155X100 |
| — | iTeos Therapeutics, Inc. | 1,745,943 | $13,409 | 1.9% | $24.67 | — | Common | 46565G104 |
| RNAC | Cartesian Therapeutics Inc | 721,139 | $12,916 | 1.8% | $19.18 | +5.6% | Common | 816212302 |
| RCKT | Rocket Pharmaceuticals, Inc. | 1,020,559 | $12,828 | 1.8% | $20.48 | -26.5% | Common | 77313F106 |
| — | Akero Therapeutics Inc | 460,617 | $12,814 | 1.8% | $25.48 | — | Common | 00973Y108 |
| TRVI | Trevi Therapeutics Inc | 3,094,896 | $12,751 | 1.8% | $2.76 | +16.2% | Common | 89532M101 |
| TWST | Twist Bioscience Corp | 267,497 | $12,431 | 1.8% | $47.58 | -5.0% | Common | 90184D100 |
| CMPX | Compass Therapeutics, Inc. | 8,567,896 | $12,423 | 1.8% | $1.57 | +5.5% | Common | 20454B104 |
| JANX | Janux Therapeutics Inc | 230,000 | $12,314 | 1.7% | $45.91 | +15.2% | Common | 47103J105 |
| REPL | Replimune Group Inc | 950,000 | $11,505 | 1.6% | $12.15 | 0.0% | Common | 76029N106 |
| NUVB | Nuvation Bio Inc | 4,164,178 | $11,077 | 1.6% | $2.57 | 0.0% | Common | 67080N101 |
| VERA | Vera Therapeutics Inc. | 257,788 | $10,902 | 1.5% | $44.28 | 0.0% | Class A Ord | 92337R101 |
| IDYA | Ideaya Biosciences, Inc. | 414,035 | $10,641 | 1.5% | $28.31 | 0.0% | Common | 45166A102 |
| RLAY | Relay Therapeutics Inc. | 2,268,825 | $9,348 | 1.3% | $10.78 | -49.5% | Common | 75943R102 |
| UTHR | United Therapeutics Corp. | 23,000 | $8,115 | 1.2% | $367.56 | 0.0% | Common | 91307C102 |
| ARCT | Arcturus Therapeutics Holdings | 459,943 | $7,805 | 1.1% | $20.05 | -6.1% | Common | 03969T109 |
| XENE | Xenon Pharmaceuticals Inc | 197,212 | $7,731 | 1.1% | $40.48 | +2.1% | Common | 98420N105 |
| STOK | Stoke Therapeutics Inc | 685,826 | $7,565 | 1.1% | $13.60 | -9.7% | Common | 86150R107 |
| AQST | Aquestive Therapeutics Inc | 1,611,833 | $5,738 | 0.8% | $3.89 | +18.5% | Common | 03843E104 |
| AXSM | Axsome Therapeutics Inc | 50,000 | $4,231 | 0.6% | $91.96 | 0.0% | Common | 05464T104 |
| — | Sutro Biopharma, Inc. | 2,160,062 | $3,975 | 0.6% | $5.65 | — | Common | 869367102 |
| HOWL | Werewolf Therapeutics, Inc. | 2,388,011 | $3,534 | 0.5% | $13.70 | -85.1% | Common | 95075A107 |
| DSGN | Design Therapeutics Inc | 559,547 | $3,452 | 0.5% | $5.79 | 0.0% | Common | 25056L103 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 1,106,851 | $3,354 | 0.5% | $13.65 | -76.0% | Common | 98943L107 |
| — | Veru Inc. | 4,285,365 | $2,788 | 0.4% | $0.65 | — | Common | 92536C103 |
| ADAPY | Adaptimmune Therapeutics plc | 5,095,912 | $2,747 | 0.4% | $0.93 | — | Sponsored ADR | 00653A107 |
| ALXO | ALX Oncology Holdings Inc. | 1,391,434 | $2,324 | 0.3% | $10.00 | -84.6% | Common | 00166B105 |
| — | Repare Therapeutics, Inc. | 1,231,154 | $1,613 | 0.2% | $31.02 | — | Common | 760273102 |